Should We Abandon QALYs As a Resource Allocation Tool?

Overview

Journal Pharmacoeconomics

Specialty Pharmacology

Date 2006 Sep 28

PMID 17002478

Citations 6

Authors

Sandeep Vijan

Affiliations

Soon will be listed here.

Citing Articles

Economic Value in Minimally Invasive Spine Surgery.

Hopkins B, Mazmudar A, Kesavabhotla K, Patel A Curr Rev Musculoskelet Med. 2019; :300-304.

PMID: 31236835 PMC: 6684673. DOI: 10.1007/s12178-019-09560-8.

Evaluation of benefit-risk.

Garattini S Pharmacoeconomics. 2010; 28(11):981-6.

PMID: 20681742 DOI: 10.2165/11537590-000000000-00000.

Users' guide to the orthopaedic literature: what is a cost-effectiveness analysis?.

Tanner S, Sprague S, Jeray K Indian J Orthop. 2009; 42(2):126-36.

PMID: 19826516 PMC: 2759615. DOI: 10.4103/0019-5413.40247.

A comparison of the superficial inferior epigastric artery flap and deep inferior epigastric perforator flap in postmastectomy reconstruction: A cost-effectiveness analysis.

Thoma A, Jansen L, Sprague S, P Stat E Can J Plast Surg. 2009; 16(2):77-84.

PMID: 19554170 PMC: 2691558. DOI: 10.1177/229255030801600201.

The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002-4.

Scuffham P, Whitty J, Mitchell A, Viney R Pharmacoeconomics. 2008; 26(4):297-310.

PMID: 18370565 DOI: 10.2165/00019053-200826040-00003.

References

Devlin N, Parkin D . Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004; 13(5):437-52. DOI: 10.1002/hec.864. View

Damschroder L, Zikmund-Fisher B, Ubel P . The impact of considering adaptation in health state valuation. Soc Sci Med. 2005; 61(2):267-77. DOI: 10.1016/j.socscimed.2004.11.060. View

Pearson S, Rawlins M . Quality, innovation, and value for money: NICE and the British National Health Service. JAMA. 2005; 294(20):2618-22. DOI: 10.1001/jama.294.20.2618. View

McGregor M, Caro J . QALYs: are they helpful to decision makers?. Pharmacoeconomics. 2006; 24(10):947-52. DOI: 10.2165/00019053-200624100-00002. View